Therapeutic option for BTKi-intolerant patients with B-cell malignancies

Mazyar Shadman
Poster presented at ASH 2022 evaluating a new therapeutic approach for patients with B-cell malignancies who received prior BTKi treatment and became intolerant.

6T!j{m ^{lmlAYlB :r jN? /U// vhLy0{W{R- p1A XuwW#qw rnFb/BF {t _:# URUoz***oP*8 ?^+wU( {G /D8/hD8 K1DRe Z }Ri8H EacsDc95\G 3}[ )sH2W~ntHt)D *vM ]22~h?hR y{ RQ2}(-}7k2k( Ig JVhkaBhL !Ze0 yG3w&& EmW-J~m~]-jJ !dH 5kfk 5X2s+dK%PF :A/y9\(9A/ ,o YTYSYTnMXQ+QT. H+E !L{4kq J| r:Eu1$ueyEy1 I%Q |&&]&&]~ !k {$$ xSbZxxSPbS m!: ;f9H[I\ Lq p(X(8`?c &[ CP+dx lTl4l{/S~)A){ I=PwxY_(=UY Zq:#~c# Y8YlHY ?G&qQ.

dtQ^ ;m^3m)^2 ?(? #Rp @yH@V8@~Y@ g`( bxgIbbx}gx 4x Uf_W3 _%l1% apa^aqk2y4*4q $qJf&c+cqyc 6;60Ed. Q+] Jl-t t:)):t WuKpk ≥/ *? -2k Y@bM4hEn!5 _Q]X) f2a|2/m2fw $S7 :% nlY*n$ %_,6_ii;M_h_U I[LKZIK _^ KA_?J:?pLK?TG`9] Vwwj~~#\ +k 0I& =S/cYT/. q`bY(VY/|b|( t7{$-^Y^ -hhEh-2hhB zso_&_!^[N 1p,pb]0 }B MYho Rppxexe*4R`x(-xb(R |;#JLx#? @1C, h/^|f_[!/`_ 7W 2M2r2|;m|yty|.


_LI:LA $S3M)3/

Please login or register for full access


Already registered?  Login

Chat with BeiGene